Gas bioengineering using hemoglobin-vesicles for versatile clinical applications

Hiromi Sakai, Shinji Takeoka, Koichi Kobayashi

    Research output: Contribution to journalArticle

    4 Citations (Scopus)

    Abstract

    Abstract: Blood transfusion systems have greatly benefited human health and welfare. Nevertheless, some problems remain: possibility of infection, blood type mismatching, immunological response, and a short shelf life that is insufficient for stockpiling for emergency situations. Realization of artificial O 2 carriers is anticipated to solve such problems. During the long development of hemoglobin (Hb)-based O 2 carriers, many side effects of cell-free Hb molecules have arisen, and have implied the physiological importance of the cellular structure of red blood cells (RBCs). Therefore, Hb-vesicles (HbVs) have been developed as artificial red cells that encapsulate a concentrated Hb solution in thin lipid bilayer vesicles. This Hb encapsulation can shield various toxic effects of molecular Hbs, especially reactions with endogenous NO and CO as vasorelaxation factors. Physicochemical analyses have clarified that Hb encapsulation retards these gaseous reactions significantly. "Gas Bioengineering" is intended to create systems using bioengineering and chemical engineering techniques to facilitate the transport of or regulate the concentration of endogenous or exogenous gaseous molecules (such as O 2, NO, and CO) that are sometimes vital and sometimes toxic to humans. Gas bioengineering using HbVs underscores the potential of HbVs as a transfusion alternative and promises its use for other clinical applications that remain unattainable using RBC transfusion.

    Original languageEnglish
    Pages (from-to)2352-2359
    Number of pages8
    JournalCurrent Pharmaceutical Design
    Volume17
    Issue number22
    DOIs
    Publication statusPublished - 2011 Jul

    Fingerprint

    Bioengineering
    Hemoglobins
    Gases
    Poisons
    Carbon Monoxide
    Chemical Engineering
    Artificial Cells
    Erythrocyte Transfusion
    Lipid Bilayers
    Cellular Structures
    Vasodilation
    Blood Transfusion
    Emergencies
    Erythrocytes
    Health
    Infection

    Keywords

    • Blood substitutes
    • Hemodynamics
    • Liposome
    • Microcirculation

    ASJC Scopus subject areas

    • Drug Discovery
    • Pharmacology

    Cite this

    Gas bioengineering using hemoglobin-vesicles for versatile clinical applications. / Sakai, Hiromi; Takeoka, Shinji; Kobayashi, Koichi.

    In: Current Pharmaceutical Design, Vol. 17, No. 22, 07.2011, p. 2352-2359.

    Research output: Contribution to journalArticle

    @article{df0be9e6c08f450e828628e62bd0db4d,
    title = "Gas bioengineering using hemoglobin-vesicles for versatile clinical applications",
    abstract = "Abstract: Blood transfusion systems have greatly benefited human health and welfare. Nevertheless, some problems remain: possibility of infection, blood type mismatching, immunological response, and a short shelf life that is insufficient for stockpiling for emergency situations. Realization of artificial O 2 carriers is anticipated to solve such problems. During the long development of hemoglobin (Hb)-based O 2 carriers, many side effects of cell-free Hb molecules have arisen, and have implied the physiological importance of the cellular structure of red blood cells (RBCs). Therefore, Hb-vesicles (HbVs) have been developed as artificial red cells that encapsulate a concentrated Hb solution in thin lipid bilayer vesicles. This Hb encapsulation can shield various toxic effects of molecular Hbs, especially reactions with endogenous NO and CO as vasorelaxation factors. Physicochemical analyses have clarified that Hb encapsulation retards these gaseous reactions significantly. {"}Gas Bioengineering{"} is intended to create systems using bioengineering and chemical engineering techniques to facilitate the transport of or regulate the concentration of endogenous or exogenous gaseous molecules (such as O 2, NO, and CO) that are sometimes vital and sometimes toxic to humans. Gas bioengineering using HbVs underscores the potential of HbVs as a transfusion alternative and promises its use for other clinical applications that remain unattainable using RBC transfusion.",
    keywords = "Blood substitutes, Hemodynamics, Liposome, Microcirculation",
    author = "Hiromi Sakai and Shinji Takeoka and Koichi Kobayashi",
    year = "2011",
    month = "7",
    doi = "10.2174/138161211797052637",
    language = "English",
    volume = "17",
    pages = "2352--2359",
    journal = "Current Pharmaceutical Design",
    issn = "1381-6128",
    publisher = "Bentham Science Publishers B.V.",
    number = "22",

    }

    TY - JOUR

    T1 - Gas bioengineering using hemoglobin-vesicles for versatile clinical applications

    AU - Sakai, Hiromi

    AU - Takeoka, Shinji

    AU - Kobayashi, Koichi

    PY - 2011/7

    Y1 - 2011/7

    N2 - Abstract: Blood transfusion systems have greatly benefited human health and welfare. Nevertheless, some problems remain: possibility of infection, blood type mismatching, immunological response, and a short shelf life that is insufficient for stockpiling for emergency situations. Realization of artificial O 2 carriers is anticipated to solve such problems. During the long development of hemoglobin (Hb)-based O 2 carriers, many side effects of cell-free Hb molecules have arisen, and have implied the physiological importance of the cellular structure of red blood cells (RBCs). Therefore, Hb-vesicles (HbVs) have been developed as artificial red cells that encapsulate a concentrated Hb solution in thin lipid bilayer vesicles. This Hb encapsulation can shield various toxic effects of molecular Hbs, especially reactions with endogenous NO and CO as vasorelaxation factors. Physicochemical analyses have clarified that Hb encapsulation retards these gaseous reactions significantly. "Gas Bioengineering" is intended to create systems using bioengineering and chemical engineering techniques to facilitate the transport of or regulate the concentration of endogenous or exogenous gaseous molecules (such as O 2, NO, and CO) that are sometimes vital and sometimes toxic to humans. Gas bioengineering using HbVs underscores the potential of HbVs as a transfusion alternative and promises its use for other clinical applications that remain unattainable using RBC transfusion.

    AB - Abstract: Blood transfusion systems have greatly benefited human health and welfare. Nevertheless, some problems remain: possibility of infection, blood type mismatching, immunological response, and a short shelf life that is insufficient for stockpiling for emergency situations. Realization of artificial O 2 carriers is anticipated to solve such problems. During the long development of hemoglobin (Hb)-based O 2 carriers, many side effects of cell-free Hb molecules have arisen, and have implied the physiological importance of the cellular structure of red blood cells (RBCs). Therefore, Hb-vesicles (HbVs) have been developed as artificial red cells that encapsulate a concentrated Hb solution in thin lipid bilayer vesicles. This Hb encapsulation can shield various toxic effects of molecular Hbs, especially reactions with endogenous NO and CO as vasorelaxation factors. Physicochemical analyses have clarified that Hb encapsulation retards these gaseous reactions significantly. "Gas Bioengineering" is intended to create systems using bioengineering and chemical engineering techniques to facilitate the transport of or regulate the concentration of endogenous or exogenous gaseous molecules (such as O 2, NO, and CO) that are sometimes vital and sometimes toxic to humans. Gas bioengineering using HbVs underscores the potential of HbVs as a transfusion alternative and promises its use for other clinical applications that remain unattainable using RBC transfusion.

    KW - Blood substitutes

    KW - Hemodynamics

    KW - Liposome

    KW - Microcirculation

    UR - http://www.scopus.com/inward/record.url?scp=80052255046&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=80052255046&partnerID=8YFLogxK

    U2 - 10.2174/138161211797052637

    DO - 10.2174/138161211797052637

    M3 - Article

    C2 - 21736544

    AN - SCOPUS:80052255046

    VL - 17

    SP - 2352

    EP - 2359

    JO - Current Pharmaceutical Design

    JF - Current Pharmaceutical Design

    SN - 1381-6128

    IS - 22

    ER -